<DOC>
	<DOCNO>NCT02942420</DOCNO>
	<brief_summary>Subjects standard regimen tiopronin ( cystine binding thiol drug ; CBTD ) plus prescribed first-line therapy ( i.e . hydration , alkali therapy dietary restriction ) fail therapy select trial . After complete informed consent , subject Screening consist medication history physical examination vital sign . Samples blood urine take clinical laboratory urinalysis . Patients undergo 12-lead ECG test . A history side effect current CBTD well laboratory recording abnormality attributable treatment also record . Subjects dose sequential manner , start low dose group ( 300 mg/day ) , proceed 600 mg.day dose group.. Safety tolerability monitor closely Independent Medical Monitor ( IMM ) base IMM 's assessment safe proceed high dose ( 600 mg/day ) , subsequent subject enrol group . Up 15 subject enrol either Group A Group B . After 7 day assign bucillamine dose , 24-hour urine sample take complete Day 8 safety visit , subject undergo 7 day washout CBTDs take . Thereafter , subject allow resume originally prescribe CBTDs Investigator 's supervision . One week follow study drug discontinuation , subject return clinic follow-up safety assessment .</brief_summary>
	<brief_title>Bucillamine Phase 2 Trial Patients With Cystinuria</brief_title>
	<detailed_description>Subjects standard regimen tiopronin ( cystine binding thiol drug ; CBTD ) plus prescribed first-line therapy ( i.e . hydration , alkali therapy dietary restriction ) fail therapy select trial . Subjects encourage continue usual self-selected ad-lib diet , fluid alkali regimen keep regimen consistent throughout duration study . Study diaries keep assess consistency drug compliance . After complete informed consent , enrol subject initial Screening interview . During interview patient assess symptom renal colic well ask schedule urological procedure ( positive indication exclusionary criterion ) . At Screening visit , medication history take complete physical examination , include vital sign do . Samples blood urine take clinical laboratory urinalysis . Patients undergo 12-lead ECG test . A history side effect current CBTD well laboratory recording abnormality attributable treatment also record . Enrolled subject dose sequential manner , start low dose group ( 300 mg/day ) . Safety tolerability monitor closely Independent Medical Monitor ( IMM ) base IMM 's assessment safe proceed high dose ( 600 mg/day ) , subsequent subject enrol group . Up 15 subject enrol either Group A Group B . Subjects stop take current CBTDs 7 day perform 24-hour urine collection Day-7 report Day 1 Visit . Subjects enrol Group A start take bucillamine tablet orally , three time day preferably 1hr 2hrs meal follow sequence ; 100 mg ( 1 tab ) morning ; 100 mg ( 1 tab ) noon 100 mg ( 1 tab ) night . This drug regimen continue 7 day . Safety Visits schedule Day 3 Day 8 ( End Study Visit ) . Furthermore , Day 7 24-hour urine collection perform . Instructions handle sample provide separate manual . Subjects enrol Group B , start take bucillamine tablet orally , three time day preferably 1hr 2hrs meal follow sequence ; 200 mg ( 2 tab ) morning ; 200 mg ( 2 tab ) noon 200 mg ( 2 tab ) night . This drug regimen continue 7 day . Safety Visits schedule Day 3 Day 8 ( End Study Visit ) . Furthermore , Day 7 24-hour urine collection perform . Instructions handle sample provide separate manual . After 7 day assign bucillamine dose provide 24-hour urine sample , complete Day 8 safety visit , subject undergo 7 day washout CBTDs take . Thereafter , subject allow resume originally prescribe CBTDs Investigator 's supervision . One week follow study drug discontinuation , subject return clinic follow-up safety assessment .</detailed_description>
	<mesh_term>Cystinuria</mesh_term>
	<mesh_term>Bucillamine</mesh_term>
	<criteria>1 . Subjects gender race ≥18 ≤80 year age 2 . Subjects proven cystinuria fail standard drug therapy tiopronin plus firstline therapy ( hydration , alkali diet restriction ) meet follow criterion . form new stone take thiol . increase stone size preexist stone take thiol . urologic intervention stone take thiol 3 . Subjects must able reliably urinate collection vessel measure urine volume 4 . Subjects must documentation stable complete blood count ( CBC ) urinalysis ( UA ) 6 month prior date enrollment 5 . Subjects may history currently active CNS disorder symptoms/effects ( e.g. , headache ) 6 . Subjects must adequate organ function , evidence follow laboratory result within 30 day prior enrollment : Absolute neutrophil count &gt; 2000 cells/mm Platelet count &gt; 140,000 cells/mm3 Hemoglobin &gt; 11.0 g/dl Albumin ≥2.5 g/dl Total bilirubin ≤1.5 upper limit normal ( ULN ) SGOT ( aspartate aminotransferase [ AST ] ) , SGPT ( alanine aminotransferase [ ALT ] ) , alkaline phosphatase ( ALP ) ≤ 2.5 x ULN eGFR &gt; 60 ml/min/173m 2 base Modification Diet Renal Disease ( MDRD ) Study equation include variable creatinine , age , sex race 7 . Female subject postmenopausal least 24 consecutive month , woman undergo surgical sterilization , ( e.g . hysterectomy , bilateral oophorectomy , tubal ligation salpingectomy ) eligible without require use contraceptive method describe Inclusion # 8 8 . For woman childbearing potential men partner childbearing potential , agreement use highly effective , nonhormonal form contraception : Acceptable form include two follow : Placement intrauterine device ( IUD ) intrauterine system ( IUS ) Condom spermicidal foam/gel/film/cream/suppository Diaphragm cervical/vault cap spermicidal foam/gel/film/cream/suppository The contraception requirement case follow : Subject surgically sterilize Subject menstrual period 12 consecutive month Contraception use continue duration study treatment least 3 month last dose study treatment Periodic abstinence ( e.g. , calendar ovulation , symptomthermal , postovulation method ) withdrawal acceptable method contraception 9 . Subjects must willing able give write informed consent 1 . Subjects renal colic 2 . Subjects schedule undergo surgical procedure 3 . Subjects Dpenicillamine ( see page 35 explanation ) 4 . Subjects cancer 5 . Subjects acute chronic infection include HIV , tuberculosis , hepatitis B hepatitis C 6 . Patients proteinuria ≥30 mg confirm repeat laboratory assessment within 24 hour 7 . Subjects QTc interval &gt; 450 m 8 . A history , hypokalemia family history Long QT syndrome 9 . Use concomitant medication may prolong QT/QTc interval 10 . Patients significant heart failure activity impairment ( Class IIIIV New York Heart Association ( NYHA ) 11 . Subjects serious hepatic disorder ( ChildPugh score B C ) 12 . Subjects history alcohol substance abuse within 12 month prior enrollment 13 . Subjects history active blood dyscrasia myelosuppression , leukopenia , granulocytopenia , thrombocytopenia , pancytopenia , aplastic anemia . 14 . Subjects Coagulopathy ( regardless control pharmacotherapy ) 15 . Subjects concomitant illness ( include active significant infection ) finding , opinion Investigator , would confound study data place subject unacceptable risk subject participate study , would require frequent adjustment concomitant medication course study 16 . Use investigational drug within 30 day prior enrollment 17 . Subjects currently participate another research study anticipate enroll participation study 18 . Subjects informed consent obtain</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>